[Multicenter experience of using Fortelyzin during staged reperfusion therapy of acute ischemic stroke in anterior circulation].

Autor:	Volodyukhin MY; Interregional Clinical and Diagnostic Center, Kazan, Russia.; Kazan State Medical Academy, Kazan, Russia.; Kazan State Medical University, Kazan, Russia., Khasanova DR; Interregional Clinical and Diagnostic Center, Kazan, Russia.; Kazan State Medical University, Kazan, Russia., Timchenko LV; Research Institute - Ochapovsky Regional Clinical Hospital No. 1, Krasnodar, Russia., Podshivalov IA; Interregional Clinical and Diagnostic Center, Kazan, Russia.; Kazan State Medical University, Kazan, Russia., Telyatnik YA; Research Institute - Ochapovsky Regional Clinical Hospital No. 1, Krasnodar, Russia., Demin TV; Interregional Clinical and Diagnostic Center, Kazan, Russia., Zagidullin BI; Hospital of Emergency Medical Care, Naberezhnye Chelny, Russia., Mukhamadieva YS; Hospital of Emergency Medical Care, Naberezhnye Chelny, Russia., Mingazetdinov MA; City Clinical Hospital No. 7, Kazan, Russia., Yusupov RI; City Clinical Hospital No. 7, Kazan, Russia., Sinutin VN; Aspectus Pharma LLC, Razvilka, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2023; Vol. 123 (6), pp. 72-77.
DOI:	10.17116/jnevro202312306172
Abstrakt:	Objective: To evaluate the safety and efficacy of Fortelyzin in the performance of staged reperfusion therapy for acute ischemic stroke (intravenous thrombolytic therapy plus mechanical thrombectomy) in anterior circulation within the FORTA RF multicenter pilot study. Material and Methods: The study included 72 patients with acute ischemic stroke in anterior circulation, who underwent staged reperfusion therapy in four vascular centers of the Russian Federation from December 2019 to January 2023. Results: The mean time from illness onset to hospitalization was 94.5 minutes in the Fortelyzin group and 97.2 min in the Actilyse group ( p =0.78). The time from the moment of hospitalization to the admission of the patient to the X-ray operating room was significantly lower in the Fortelyzin group ( p =0.002). The incidence of symptomatic hemorrhagic transformations in the Fortelyzin group was 6%, in the Actilyse group - 8% ( p =0.75). A favorable functional outcome in the first group was observed in 47% of patients, in the control group in 42% ( p =0.66). Mortality in both groups did not differ significantly and amounted to 22% and 25%, respectively. Conclusion: The first results of the FORTA RF multicenter study demonstrate the safety and efficacy of Fortelyzin in staged reperfusion therapy compared to Actilyse.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu